Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦

@pabeda1

Cardiologist, Associate Prof. of Internal Medicine, Rio de Janeiro State University. Passion for preventive Cardiology, heart failure, art and classical music

Rio de Janeiro, Brasil Joined October 2012

844 Following 5.5K Followers 17K Posts

Latest posts 5

Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1 1d

Bookmark in your calendar, this will be an exciting open webinar. October 30th, 12:00 CET time. @society_eas @rauldsf_santos #atherosclerosis #cholesterol #lipids #CardioX

Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1 Oct 19

👇👇

European Atherosclerosis Society Verified account @society_eas Oct 19

The LCN webinar series on the Optimal Clinic continues! Learn about practical recommendations for organising, strengthening, and harmonising lipid clinics across different healthcare settings. The series focuses on key elements such as education and training, staffing structures, patient pathways, national registries, and healthcare policy.

The overall aim is to improve the prevention of atherosclerotic cardiovascular disease (ASCVD) and other lipid-related disorders, while also promoting more efficient use of healthcare resources.

But what does this look like in Brazil? Join us for this event, chaired by Prof. @pabeda1 & Dr Fabiana Rached and gain an overview of the local landscape: eas.to/LCNWebOCBra

View quoted post on X

Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1 Oct 9

Honoured to share the joint session of @escardio - World Heart Federation - @sbc_cientifico on coronary artery disease at the World Congress of Cardiology - with distiguished colleagues Sergio Montenegro, Amam Mbakwen, Franz Weidinger, Julie Redfern and Carlos Aguiar
#Cardiology

Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1 Sep 7

Now there's only ARTEMIS left ongoing. Not too many reasons to be optimist...🙄
#inflammation #cardiovascular #ziltivekimab #atherosclerosis
👇👇
clinicaltrialsarena.com/news/novo-nord…

www.clinicaltrialsarena.com Novo Nordisk’s ziltivekimab stumbles again on pair of Phase III terminations Novo Nordisk terminates two Phase III studies of ziltivekimab in cardiovascular disease and chronic kidney disease following efficacy reviews.

Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1 Aug 21

👇👇👇

Ricardo Lopez Santi @Risantilopezcar Aug 20

Abrir oportunidades de cooperación es esencial para mejorar indicadores que no nos favorecen cuando analizamos que cerca de 350.000 muertes cardiovasculares anuales en America Latina y el Caribe son prematuras. Estamos trabajando en eso desde la @SIAC_cardio
View quoted post on X